How to Decide Whether a Visit Is Worth It

What to weigh before spending money

Consider the full price, how long any relief may last, and other care. An uncertain result shouldn't keep you from paying for medicine, food, or later care. Check whether you could still afford physical therapy or a surgery visit. Financing can keep adding interest after the medical choice is over.

Your knee also needs a proper exam. With severe wear, poor balance, or major daily limits, a big drop in soreness may be less likely. Walking much farther may be less likely too. An X-ray doesn't decide everything, but it helps explain the joint. Sleep, strength, walking, and earlier care matter as well.

The value comes down to daily improvement for the money.

What to settle during the consultation

The QC Kinetix team may discuss platelet-rich plasma (PRP), a regenerative treatment using blood drawn from you. The blood goes through a spinning machine that separates the platelets. The resulting liquid is placed into the knee at the clinic. They'll review your history and explain which choices may suit your soreness.

Ask when a change might appear and how long it could last. Find out what would lead the team to suggest different care. Take the X-ray report, medicine list, and notes from prior visits. Written details mean you don't have to trust your memory.

The clearest answer may be that this care isn't right for your knee now.

When to stop weighing options and get help

A hot knee, marked swelling, and fever need same-day medical care. Sudden trouble bearing weight after an injury also needs prompt attention. Don't book routine care for a knee stuck at an odd angle or locked.

Get timely help for fast-worsening night soreness or unexplained weight loss. Numbness, weakness, or loss of bladder control needs urgent care too. Several swollen joints with long morning stiffness may need a rheumatologist. That's a doctor who handles arthritis and swelling across several joints.

These symptoms need care before any treatment discussion.

Sources

1. A randomized, double-blind, placebo-controlled trial in a Japanese population tested leukocyte-POOR PRP specifically in mild-to-moderate knee OA WITH joint effusion or bone marrow lesions - i.e. a selected inflammatory phenotype rather than all comers. Recorded here because phenotype selection, not the product, is the most plausible explanation for why PRP trials disagree with one another.

   Yoshioka T, et al. — The Effectiveness of Leukocyte-Poor Platelet-Rich Plasma Injections for Symptomatic Mild to Moderate Osteoarthritis of the Knee With Joint Effusion or Bone Marrow Lesions in a Japanese Population: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.. The American journal of sports medicine, 2024. DOI: 10.1177/03635465241263073.

2. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. The journal of knee surgery, 2018. DOI: 10.1055/s-0037-1604443.

5. In a randomized trial of 100 patients with moderate-to-severe knee OA eligible for total knee replacement, TKR followed by 12 weeks of non-surgical care improved the KOOS4 score more than the same non-surgical programme alone (32.5 vs 16.0 points; adjusted mean difference 15.8, 95% CI 10.0 to 21.5) — but produced four times as many serious adverse events (24 vs 6, P=0.005), and 26% of the non-surgical group had chosen surgery within 12 months, meaning roughly three-quarters had not.

   Skou ST, Roos EM, Laursen MB, et al. — A Randomized, Controlled Trial of Total Knee Replacement.. New England Journal of Medicine, 2015. DOI: 10.1056/NEJMoa1505467.

6. A prospective longitudinal study of 64 patients with acute medial meniscus posterior root tear managed non-operatively found 76.6% continued non-operative care and only 23.4% converted to surgery (median 6 months). Pain fell from 7.6 to 1.3 on an 11-point scale within 6 months and stayed there — even though structural degeneration on MRI progressed. Symptoms and structure moved in opposite directions.

   Knee Surgery, Sports Traumatology, Arthroscopy authors — Clinical improvement despite structural degeneration after nonoperative treatment of medial meniscus posterior root tear: A prospective longitudinal study.. Knee Surgery, Sports Traumatology, Arthroscopy, 2026. DOI: 10.1002/ksa.70570.